Heena Sharma Blog

French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential Covid-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated. Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021. "We are being guided by our dialogue with regulatory authorities," Sanofi research chief John Reed told reporters, when asked about the accelerated time frame. Read More

CRISIL RESEARCH expects the prospects of small and medium enterprises ( SMEs ) making bulk drugs to improve in the near term, because of their sharp focus on developing niche and complex molecules. These are difficult to manufacture but command a higher premium. Strong demand for formulations and increasing health insurance penetration would also support growth. Developments in China have been impacting bulk-drugs players in India. Recently,quality issues with Chinese active pharmaceutical ingredients in hypertension drugs had prompted a global recall. That prompted multinationals to look at alternative sources such as India. Further, the recent clampdown on polluting industries in China had led to a shutdown of several bulk-drug factories. Read More